^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CRTE7A2-01

    i
    Other names: CRTE7A2-01, CRTE7A2-01 TCR-T cell therapy
    Associations

    News

    Trials
    Company:
    CorreGene
    Drug class:
    HPV-16 E6 protein inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Corregene Biotechnology Co., Ltd
    New P1 trial • Metastases
    |
    cyclophosphamide • CRTE7A2-01
    over2years
    CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers (clinicaltrials.gov)
    P1, N=12, Recruiting, Corregene Biotechnology Co., Ltd | Not yet recruiting --> Recruiting | Initiation date: Dec 2021 --> Jul 2022
    Enrollment open • Trial initiation date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    cyclophosphamide • fludarabine IV • CRTE7A2-01